Creative Biolabs' exposure-responsive transcriptome analysis service streamlines toxicological risk assessment and clarifies multi-factor interactions through dynamic RNA-Seq profiling and specialized factor interaction modeling. This ensures regulatory submission readiness. This specialized service provides molecular-level data critical for classifying risks associated with single factors or complex mixtures, enabling the shift from basic hazard identification to mechanism-based risk characterization. By identifying key transcription changes triggered by the exposome, we provide the dynamic molecular evidence necessary to support regulatory filings and accelerate your project.

Introduction to Exposure-Responsive Transcriptome Analysis Service

Transcriptome analysis provides an unbiased, high-resolution view of all active genes in a cell following an exposure event. In the context of carcinogenesis, quantifying changes in mRNA over time (especially at low, chronic doses) is crucial for identifying the earliest molecular events that drive malignant transformation. This approach allows researchers to distinguish reversible cellular adaptation from irreversible, pre-neoplastic changes and, most importantly, provides the statistical foundation for integrated carcinogenic factor analysis, where the collective risk of complex mixtures is accurately modeled based on their genomic impact.

Key Problem-Solving Capabilities

Contact us today to schedule a confidential consultation and receive a custom project proposal.

Multi-Factor Workflow for Carcinogenic Risk Assessment

Our service implements a rigorous, multi-stage workflow designed to handle the complexity of integrated factor analysis, ensuring clarity and traceability from sample submission to the final regulatory report.

Publication

This study identifies key molecular modifiers of response to the CHK1 inhibitor prexasertib through transcriptomic analysis of sensitive and resistant models. It reveals that sensitivity is associated with an E2F/G2M replication stress signature, while resistance is linked to innate immune signaling. Both intrinsic and acquired resistance involve upregulation of interferon and STING pathway genes. These findings elucidate dual resistance mechanisms and suggest innate immunity as a potential therapeutic target to enhance prexasertib efficacy.

Fig.1 Transcriptomic GSEA reveals mechanisms of acquired prexasertib resistance in seven cancer cell lines. ¹

Why Choose Us?

Creative Biolabs is uniquely positioned at the intersection of genomics and regulatory toxicological science, minimizing assessment risk and maximizing risk classification clarity. Our key advantage is the ability to apply specialized statistical models that move beyond simple linear responses to accurately quantify synergistic or antagonistic transcriptional effects from co-exposure. This advanced modeling for multi-factor synergy allows clients to pinpoint whether a mixture's risk is greater than the sum of its parts. This capability is essential for establishing regulatory compliance in complex multi-contaminant scenarios, providing the robust data needed for environmental and occupational safety assessments.

Is your research dealing with complex factor interactions? Inquire with Creative Biolabs today for a detailed protocol on our multi-factor synergy modeling.

FAQs

Customer Review

• Predictive Power
  The correlation modeling against our historical IC50 data was excellent, clearly showing the E2F target genes as baseline predictors of sensitivity. It streamlined our patient stratification strategy for the trial. – J***na S***er
• Integrated Insight
  We sent them transcriptomics and companion metabolomics data. Their joint pathway analysis built a comprehensive network view that confirmed the genetic changes were biochemically realized, providing the evidence we needed to support our regulatory submission. – R***l M***os

Related Services

To further support your toxicological and regulatory goals, Creative Biolabs offers several complementary services:

How to Contact Creative Biolabs

Creative Biolabs' exposure-responsive transcriptome analysis service provides the definitive molecular evidence required to understand multi-factor risk, classify carcinogenic mechanisms, and define predictive biomarkers. By leveraging state-of-the-art RNA-Seq and pioneering bioinformatic correlation modeling, we deliver actionable insights that accelerate your toxicological risk characterization. Partner with Creative Biolabs to transform your safety data into regulatory and commercial success.

Reference

1. Blosser, Wayne D., et al. "A pan-cancer transcriptome analysis identifies replication fork and innate immunity genes as modifiers of response to the CHK1 inhibitor prexasertib." Oncotarget 11.3 (2020): 216. Distributed under Open Access license CC BY 3.0, without modification. https://doi.org/10.18632/oncotarget.27400

For Research Use Only | Not For Clinical Use